June 4, 2026 — Abbisko Therapeutics (HKEX: 02256) announced that the company presented two model-based drug development advances in poster sessions at the Population Approach Group Europe (PAGE) Meeting, held from June 2 to 5, 2026, in Dubrovnik, Croatia.

The presentations highlighted a novel joint modeling framework to predict progression-free survival (PFS) for ABSK-011, a highly selective FGFR4 inhibitor, in patients with advanced FGF19+ hepatocellular carcinoma (HCC). Additionally, Abbisko Therapeutics, together with an external collaborator, presented a population pharmacokinetic modeling study of ABSK-011 using Maspectra, an innovative modeling software independently developed in China, including a comparative analysis with NONMEM.

• Title: Predicting progression-free survival for ABSK-011 (irpagratinib) in advanced FGF19+ HCC patients via joint modeling of tumor growth dynamics

• Date/Time: Wed, Jun 3, 2026 10:30AM–12:00PM (CEST)

• Presentation #: 12177

• Title: Comparison of Maspectra and NONMEM for Population Pharmacokinetic Modeling: An ABSK-011 (irpagratinib) Case Study

• Date/Time: Wed, Jun 3, 2026 10:30AM–12:00PM (CEST)

• Presentation #: 12072

At this PAGE Meeting, Abbisko Therapeutics showcased two model-based drug development advances, highlighting the company's growing expertise in quantitative pharmacology and innovative modeling methodologies. Notably, the joint TGD-PFS modeling framework for ABSK-011 represents a significant contribution to the field, offering a more robust approach to support clinical decisions and pivotal trial design. Additionally, the comparative study of Maspectra and NONMEM demonstrates Abbisko's proactive engagement in the practical application of a domestically developed modeling software from China, reflecting the company's commitment to supporting homegrown technologies. These efforts underscore Abbisko's dedication to both advancing its pipelines and contributing to the evolution of model-based drug development paradigms.

Looking ahead, Abbisko Therapeutics will continue to focus on addressing unmet medical needs and accelerating the translation of innovative discoveries into clinical applications, with the goal of delivering more first-in-class and best-in-class therapies to patients worldwide.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.